December 23rd 2024
According to Mile Brujic, OD, FAAO, low-level light therapy (LLLT) and intense pulsed light have demonstrated tremendous benefits for his patients.
Current, Relevant, Useful: Key Takeaways from the CRU Eye Symposium (CME Credit)
View More
Current, Relevant, Useful: Key Takeaways from the CRU Eye Symposium (COPE Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
Illuminating the Power of Collaborative Care in nAMD and DME: Advancing the Shift to Treatment Innovations
February 2, 2025
Register Now!
EnVision Summit
February 14-17, 2025
Register Now!
Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
March 9, 2025
Register Now!
CRU Eye Symposium
March 28-30, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)
View More
19th Annual Controversies in Modern Eye Care
May 4, 2025
Register Now!
(CME Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(COPE Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (CME Track)
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (COPE Track)
View More
Collaborative Care Symposium
May 30-31, 2025
Register Now!
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Topline results from Ersa Phase 2a trial revealed by Tarsus
December 11th 2023TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.
BREAKING NEWS: FDA approves lotilaner ophthalmic solution 0.25% for treatment of Demodex blepharitis
July 25th 2023According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.
Cosmetic dangers: Part 2-Products banned by the FDA, worsen ocular surface disease
March 14th 2018In Part 2 of her three-part series on cosmetic dangers, Tracy Schroeder-Swartz, OD, MS, FAAO, focuses on the dangers found in cosmetics-particularly cosmetics banned by the FDA and those that may exacerbate ocular surface disease.
Preparing the periocular region for surgery
February 21st 2018Preparing a patient for ocular surgery can pose challenges with cosmetics being widely used. Marc Bloomenstein, OD, with the advice of Optometry Times Editorial Advisory Board member Whitney Hauser, OD, discusses the importance of properly preparing cosmetic users for eye surgery.
Why you should add upper lid eversion to your comprehensive exam
January 26th 2018Comprehensive ocular examinations can provide an OD with an inside look into a patient's health. Mile Brujic, OD, and David Kading, OD, discuss the importance of using upper eyelid eversion during the exam to unleash significant information about a patient's ocular surface and systemic health.
How to treat patients with delusional parasitosis
November 14th 2017Delusional parasitosis or Ekbom’s syndrome is a patient’s mistaken belief that he is infested by parasites such as mites, lice, fleas, spiders, worms, bacteria, or other organisms. Scott Schachter, OD, discusses the challenges ODs face when working with these patients.
Treating blepharitis in the pediatric population
June 1st 2017When your pediatric patient presents with irritated, itchy eyelids with reddened lid margins, diagnosing blepharitis may be the easy part of patient care. Implementing a treatment regimen for patients who are infants, toddlers, or school-age children, requires optometrists to use not only their knowledge but their clinical art of practice as well.